The ongoing shortage of medications continues to pose a significant challenge to the pharmaceutical sector in Spain, and increasingly, across Europe. A recent report, the III Report on Medicine Shortages from LUDA Partners, reveals a concerning trend: a quarterly average of 5,397 different products experiencing supply issues in pharmacies within their network during 2025. This represents an 8% increase compared to the previous year, highlighting a growing crisis that impacts patient care and strains healthcare systems. The situation isn’t limited to Spain; medicine shortages are a global concern, driven by complex factors ranging from manufacturing delays and geopolitical instability to increased demand and economic pressures.
The LUDA Partners report, based on data collected through a network of over 3,700 pharmacies nationwide, underscores the critical role of technology in mitigating the effects of these shortages. Their platform has reportedly helped over 600,000 patients continue their treatments without interruption, demonstrating the potential of digital solutions to improve access to essential medicines. However, the increasing frequency and breadth of shortages necessitate a multi-faceted approach involving collaboration between pharmaceutical companies, regulators, and healthcare providers. The impact extends beyond inconvenience; delays in treatment can lead to worsening health outcomes and increased healthcare costs.
The challenges aren’t uniform across all therapeutic areas. According to the LUDA report, antidiabetic medications, antibacterial drugs, and antidepressants are currently experiencing the most significant supply disruptions. Specifically, treatments for diabetes account for 10% of the medications located through the LUDA tool, with Ozempic and Saxenda being particularly affected. Antibacterial agents represent 7% of shortages, with Furantoina and Zinnat facing the most difficulties, while antidepressants comprise 5%, with Anafranil being prominently impacted. These shortages are particularly concerning given the prevalence of these conditions and the critical need for uninterrupted treatment. The reasons behind these specific shortages are varied, ranging from manufacturing issues to increased demand driven by factors like rising rates of diabetes and respiratory infections.
The Evolving Landscape of Medicine Shortages
While Ozempic has become a well-known example of a medication facing supply challenges, the LUDA report emphasizes that shortages are not limited to single drugs or temporary demand spikes. The issues stem from multiple factors affecting the entire supply chain, indicating a systemic problem. In 2024, Concerta, a medication used to treat attention-deficit/hyperactivity disorder (ADHD), surpassed Ozempic as the most frequently unavailable drug, particularly during the back-to-school season. In 2025, Anafranil, an antidepressant, topped the list during the summer months. Currently, in early 2026, Lenzetto, a hormone therapy medication used to treat symptoms of menopause, is experiencing the highest number of reported incidents.
This evolving pattern underscores that no therapeutic area is immune to supply disruptions. The need for effective strategies to ensure patients can continue their treatments quickly and reliably is paramount. This is particularly critical given reports of severe, even fatal, consequences in other countries resulting from medicine shortages. The European Medicines Agency (EMA) has been actively monitoring and addressing medicine shortages across the European Union, issuing guidance to member states and working with manufacturers to identify and resolve supply chain vulnerabilities. The EMA’s Supply Group plays a key role in coordinating these efforts.
Impact on Regional Pharmacies
The LUDA report specifically highlights the impact of shortages on pharmacies in Castilla La Mancha, Spain. Treatments for diabetes are particularly affected in this region, accounting for 10% of the medications located through the LUDA tool. Ozempic and Saxenda are among the most frequently sought-after medications experiencing shortages. Antibacterial drugs are the second most affected category, with Furantoina and Zinnat facing significant supply issues, representing 7% of located medications. Antidepressants, specifically Anafranil, account for 5% of the shortages. These regional variations underscore the need for localized strategies to address supply chain vulnerabilities and ensure equitable access to essential medicines.
Luis Martín Lázaro, co-founder of LUDA Partners, emphasizes that medicine shortages are a systemic problem affecting the entire healthcare system. He argues that while there are no definitive solutions, implementing measures to mitigate the impact is crucial. “Technology has become a great ally in solving complex problems, and the pharmaceutical sector is no exception,” Lázaro stated. “LUDA is an example of how technology can help mitigate the consequences of shortages.” The company’s platform leverages real-time data to help pharmacists locate available medications, reducing the burden on patients and healthcare providers.
The Role of Technology and Innovation
The increasing reliance on technology, such as the LUDA platform, reflects a broader trend towards digital solutions in healthcare. Artificial intelligence (AI) is similarly playing a growing role in predicting and preventing medicine shortages. LUDA Partners has recently incorporated an AI-powered system, LUDA Trends, designed to anticipate potential supply disruptions by analyzing data on drug availability and demand. This proactive approach allows pharmacies to prepare for shortages and minimize their impact on patients. The company is assisting pharmacies in obtaining Distafarma certification, enabling them to sell over-the-counter (OTC) medications online, expanding access to care and reducing the strain on traditional pharmacy channels.
The shift towards digital healthcare solutions is not without its challenges. Data privacy and security concerns, the need for interoperability between different systems, and the digital divide – ensuring equitable access to technology for all patients – are all crucial considerations. However, the potential benefits of leveraging technology to improve medicine access and supply chain resilience are significant. The ongoing development and implementation of innovative solutions, like LUDA’s platform and AI-powered forecasting tools, are essential steps towards addressing the growing challenge of medicine shortages.
Key Takeaways:
- Medicine shortages are increasing in Spain and globally, impacting access to essential treatments.
- Antidiabetic, antibacterial, and antidepressant medications are currently experiencing the most significant supply disruptions.
- Technology, such as the LUDA platform and AI-powered forecasting tools, is playing a crucial role in mitigating the impact of shortages.
- A multi-faceted approach involving collaboration between pharmaceutical companies, regulators, and healthcare providers is needed to address the systemic causes of medicine shortages.
- Regional variations in shortages highlight the need for localized strategies to ensure equitable access to medications.
Looking ahead, the European Commission is expected to release a new strategy on pharmaceutical supply chain resilience in the coming months, outlining measures to strengthen the EU’s ability to prevent and respond to medicine shortages. This strategy is expected to focus on diversifying supply sources, promoting domestic manufacturing, and improving data sharing and transparency across the supply chain. The ongoing dialogue between stakeholders and the continued development of innovative solutions will be critical to ensuring a stable and reliable supply of medicines for patients across Europe.
What are your thoughts on the growing issue of medicine shortages? Share your experiences and perspectives in the comments below. And please, share this article with your network to raise awareness about this critical healthcare challenge.